Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously-Treated Solid Tumors and Hematologic Malignancies

NCT03082209 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03082209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03082209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously-Treated Solid Tumors and Hematologic Malignancies
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2017
Completion date
January 21, 2022
Enrollment
153 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cancer, hematologic malignancies